 Akouos Inc. disclosed Thursday that its initial public offering of shares has been upsized by 50, and the expecting pricing has increased, as the genetic medicine company focused on the treatment of hearing loss now looks to raise 212.5 million. The company is selling 12.5 million shares in the IPO, up from 8.33 million, while the expected IPO price increased to 17 a share from 14 to 16. The stock will list on the Nasdaq under the ticker symbol AKUS. With 32.48 million shares to be outstanding after the IPO, Akouos will be valued at 552.2 million. If the underwriters of the IPO, led by BofA Securities, Cowen and Piper Sandler, exercise all the options to buy additional shares, Akouos could raise 244.4 million and be valued at 584.1 million. The company recorded a net loss of 10.4 million on no revenue during the three months ended March 31, compared with a loss of 5.9 million on no revenue over the same period a year ago, while operating expenses rose to 10.5 million from 3.8 million. The company is looking to go public at a time that the Renaissance IPO ETF has rallied 58.5 over the past three months, while the SP; 500 has climbed 23.3. 